MAP2K1 and neuropathy: In 2014 [25] we have already shown that administration of NF-kappaB inhibitor (parthenolide) as well as MEK1/2 inhibitor (U0126) diminished pain symptoms and enhanced morphine effectiveness in a rat model of neuropathy.